

Type:
Oncology

Geography:
Europe

Study Type:
Phase II & III
Program

Client:
Research
Consortium/
Academic Group

PROJECT SUMMARY:

An oncology research group approached Excelya to provide clinical monitoring services of a Phase II melanoma/BRAF gene mutation study, which developed into an ongoing partnership and program of 5 Phase II and III oncology studies .

- Involving total of >80 sites and >1000 patients
- Countries: Spain, Portugal, Germany, Italy, UK, France, Belgium, Netherlands

Objective

Collaborate with Research Group to provide international clinical monitoring services as an extension of their team

Study Challenges:

- 1) The Sponsor needed a flexible and cost effective solution to scale monitoring from one project to multiple projects across EU
- 2) Fluctuation in study demands and complexities , and variations in recruitment across sites, impacted monitoring workloads
- 3) The Sponsor had to manage study within budget framework, which was getting burned too quickly

Excelya Solutions:

- 1) Excelya expanded the local team from one country to eight, providing high calibre CRAs across the platform with a delivery and oversight model to ensure high quality monitoring
- 2) Excelya structured an **innovative resourcing model** by utilizing our internal resources and network, to meet study demands, with the flexibility to adapt workload across full and partial FTEs
- 3) **Optimised monitoring strategy** and frequency to reduce travel time and manage costs within budget; and developed a cost model to give Sponsor improved predictability of spend

Key info:

5
Studios

8
Countries

80
Sites

Partnership
since 2016

Excelya's impact:

Excelya **reduced the overall costs**, helping the client manage the study **within budget**.

The project **evolved into a partnership** (7 years total) for clinical monitoring services.